Association of Relapse of Clostridium difficile Disease with BI/NAP1/027

被引:103
|
作者
Marsh, Jane W. [1 ,2 ]
Arora, Rangolee [3 ]
Schlackman, Jessica L. [1 ,2 ]
Shutt, Kathleen A. [1 ,2 ]
Curry, Scott R. [1 ,2 ]
Harrison, Lee H. [1 ,2 ]
机构
[1] Univ Pittsburgh, Sch Med, Div Infect Dis, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA
[3] Westmoreland Reg Hosp, Div Infect Dis, Greensburg, PA USA
关键词
TANDEM-REPEAT ANALYSIS; RESTRICTION-ENDONUCLEASE ANALYSIS; BI STRAIN; INFECTION; REINFECTION; DIARRHEA; VANCOMYCIN; EPIDEMIOLOGY; SURVEILLANCE; FIDAXOMICIN;
D O I
10.1128/JCM.02291-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Recurrent Clostridium difficile infection (CDI) occurs in up to 35% of patients. Recurrences can be due to either relapse with the same strain or reinfection with another strain. In this study, multilocus variable-number tandem-repeat analysis (MLVA) was performed on C. difficile isolates from patients with recurrent CDI to distinguish relapse from reinfection. In addition, univariate and multivariate analyses were performed to identify risk factors associated with relapse. Among patients with a single recurrence, relapse due to the original infecting strain was more prevalent than reinfection and the interval between episodes was shorter than among patients who had reinfections. Among patients with >1 recurrence, equal distributions of relapse and reinfection or a combination of the two episode types were observed. Initial infection with the BI/NAP1/027 epidemic clone was found to be a significant risk factor for relapse. This finding may have important implications for patient therapy. Classification of recurrent CDI episodes by MLVA can be utilized to make informed patient care decisions and to accurately define new CDI cases for infection control and reimbursement purposes.
引用
收藏
页码:4078 / 4082
页数:5
相关论文
共 50 条
  • [21] Poor yield of Clostridium difficile testing algorithms using glutamate dehydrogenase antigen and C difficile toxin enzyme immunoassays in a pediatric population with declining prevalence of clostridium difficile strain BI/NAP1/027
    Gomez, Emily J.
    Montgomery, Sandra
    Alby, Kevin
    Robinson, Diana P.
    Roundtree, Sylvester S.
    Blecker-Shelly, Deborah
    Sullivan, Kaede V.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 91 (03) : 229 - 232
  • [22] Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting
    Venugopal, Anilrudh A.
    Riederer, Kathleen
    Patel, Shilpa M.
    Szpunar, Susanna
    Jahamy, Houssein
    Valenti, Sharon
    Shemes, Stephen P.
    Khatib, Riad
    Johnson, Leonard B.
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 44 (04) : 243 - 249
  • [23] Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027
    Wieczorkiewicz, Jeffrey T.
    Lopansri, Bert K.
    Cheknis, Adam
    Osmolski, James R.
    Hecht, David W.
    Gerding, Dale N.
    Johnson, Stuart
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) : 418 - 423
  • [24] Differential Immunodetection of Toxin B from Highly Virulent Clostridium difficile BI/NAP-1/027
    Pollock, Nira R.
    Song, Linan
    Zhao, Mingwei
    Duffy, David C.
    Chen, Xinhua
    Sambol, Susan P.
    Gerding, Dale N.
    Kelly, Ciaran P.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2015, 53 (05) : 1705 - 1708
  • [25] Novel target and PCR assay for identification of hypervirulent ST1 (BI/ NAP1/027) Clostridioides difficile and detection of toxigenic C. Difficile
    Li, Zhirong
    Ouyang, Zirou
    Zhang, Huimin
    Mi, Chaoyi
    Dong, Ning
    Niu, Yanan
    Qiang, Cuixin
    Yang, Jing
    Wang, Weigang
    Li, Yanhong
    Zhao, Jianhong
    CLINICA CHIMICA ACTA, 2024, 559
  • [26] Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/ 027 strain across the United States Veterans Health Administration
    Gentry, Chris A.
    Williams II, Riley J.
    Campbell, Darien
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2021, 100 (02)
  • [27] Evaluation of the Cepheid Xpert Clostridium difficile Epi Assay for Diagnosis of Clostridium difficile Infection and Typing of the NAP1 Strain at a Cancer Hospital
    Babady, N. Esther
    Stiles, Jeffrey
    Ruggiero, Phyllis
    Khosa, Perminder
    Huang, David
    Shuptar, Susan
    Kamboj, Mini
    Kiehn, Timothy E.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (12) : 4519 - 4524
  • [28] Diversity of multidrug-resistant epidemic Clostridium difficile NAP1/RT027/ST01 strains in tertiary hospitals from Honduras
    Hidalgo-Villeda, Fanny
    Tzoc, Edgardo
    Torres, Luque
    Bu, Efrain
    Rodriguez, Cesar
    Quesada-Gomez, Carlos
    ANAEROBE, 2018, 52 : 75 - 78
  • [29] Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B
    Devera, T. Scott
    Lang, Gillian A.
    Lanis, Jordi M.
    Rampuria, Pragya
    Gilmore, Casey L.
    James, Judith A.
    Ballard, Jimmy D.
    Lang, Mark L.
    INFECTION AND IMMUNITY, 2016, 84 (01) : 194 - 204
  • [30] Recurrent disease due to ribotype 027 Clostridium difficile
    Rodriguez-Villodres, Angel
    Praena, Julia
    Reyes Vidal-Acuna, Maria
    Aznar, Javier
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2016, 34 (07): : 461 - 462